Presentation ESC 2017

Clinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial

Presenter: Robert Giugliano

REGISTER for free or LOG IN to view this content

Clinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial
Clinical Cardiology
Clinical Pharma
Lipids
Prevention
Coronary
ACS/AMI
CAD Pharma
Presentation
ESC 2017

Up Next

More slides +

We Recommend